Sruthi Vellanki

Sourced from institutional research profiles (UAMS TRI or ARA).

Assistant Professor

UAMS

COM | Internal Med Hem-Onc

4 h-index 37 pubs 52 cited

Research Areas

Biomedical Subjects

Links

Research Group UAMS TRI Profile

Edit your profile

OverviewAI-generated summary

Sruthi Vellanki, Assistant Professor in Internal Medicine at the University of Arkansas for Medical Sciences, investigates infection-free survival and the effects of intravenous immunoglobulin (IVIG) supplementation in patients undergoing therapy for multiple myeloma. Her research includes studies on BCMA-directed bispecific antibody therapy and teclistamab therapy, examining the role of IVIG in managing infections in these patient populations. Vellanki also contributes to literature on rare complications and management strategies, including hyperhemolysis in sickle cell disease and percutaneous intervention for endocarditis in high-risk patients. Her work also touches upon the stem cell origin of cancer and the clinical implications for drug and therapy development, as well as rare thrombotic complications of COVID-19 and atypical presentations of acute lymphoblastic leukemia. Vellanki has published 37 papers, with an h-index of 4 and 52 citations.

Metrics

h-index: 4
Publications: 37
Citations: 52

Selected Publications

Immunotherapy role in bladder cancer treatment: a review of literature (2026)

Frontiers in Oncology DOI OpenAlex
POSTER: CLL-1382: Comparing Ibrutinib With Acalabrutinib and Zanubrutinib in B-Cell Malignancies: A Real-World Study of Mortality and Toxicity (2026)

Clinical Lymphoma Myeloma & Leukemia DOI OpenAlex
CLL-1382: Comparing Ibrutinib With Acalabrutinib and Zanubrutinib in B-Cell Malignancies: A Real-World Study of Mortality and Toxicity (2026)

Clinical Lymphoma Myeloma & Leukemia DOI OpenAlex
Prognostic impact of lymphocyte kinetics and immune composition during bispecific antibody therapy in relapsed/refractory multiple myeloma (2026)

Blood Cancer Journal DOI OpenAlex
Acute Kidney Injury in Recipients of Chimeric Antigen Receptor T-Cell therapy: Clinical Characteristics and Impact on Mortality (2026)

Transplantation and Cellular Therapy DOI OpenAlex
Cardiovascular Autonomic Dysfunction in Cancer Therapy: Clinical Manifestations and Management (2026)

Cardiology Research DOI OpenAlex
The prognostic impact of lymphocyte counts and immune composition in bispecific antibody therapy in relapsed/refractory multiple myeloma (2026)

Research Square DOI OpenAlex
Social vulnerability index as an independent poor prognostic factor in patients with chronic hematological malignancies in Arkansas. (2026)

Journal of Clinical Oncology DOI OpenAlex
Influence of genomic and clinical high-risk features on outcomes after BCMA-directed bispecific antibody therapy in relapsed/refractory multiple myeloma. (2026)

Journal of Clinical Oncology DOI OpenAlex
26-A-9693-ACC PREDICTION OF 1-YEAR MAJOR ADVERSE CARDIAC EVENTS IN CAR-T RECIPIENTS USING RISK SCORE MODELING: EXPANDED WHOLE-COHORT ANALYSIS (2026)

Journal of the American College of Cardiology DOI OpenAlex
26-A-11133-ACC CYTOKINE RELEASE SYNDROME-GUIDED RISK MODELS REDEFINE CARDIOTOXICITY SURVEILLANCE: OPTIMIZING DETECTION OF CANCER THERAPY-RELATED CARDIAC DYSFUNCTION AND ADVERSE CARDIOVASCULAR EVENTS AFTER CAR-T THERAPY (2026)

Journal of the American College of Cardiology DOI OpenAlex
AKI in Patients Receiving Chimeric Antigen Receptor T Cells: Risk Factors and Characteristics (2025)

Journal of the American Society of Nephrology DOI OpenAlex
Navigating Hyperhemolysis in Sickle Cell Disease: Insights from Literature (2025)

Diagnostics 8 citations DOI OpenAlex
Role of proliferation-related genes as predictive factors for adjuvant therapy in colon cancer. (2025)

Journal of Clinical Oncology DOI OpenAlex
Epidemiological and clinical trends in common hematological malignancies in Arkansas: Arkansas Central Cancer Registry (ACCR)-based study. (2025)

Journal of Clinical Oncology DOI OpenAlex